Literature DB >> 2245966

Growth hormone and body composition.

B A Bengtsson1, R J Brummer, I Bosaeus.   

Abstract

Through its anabolic, lipolytic and antinatriuretic actions, GH has profound effects on body composition. In untreated acromegaly, body weight, body cell mass and extracellular water are increased simultaneously with a decrease of body fat. After successful treatment, extracellular water and body fat normalize, but cell mass remains high. The changes in cell mass, body fat and extracellular water observed in acromegaly suggest different dose-response relationships between GH and these parameters. The relationship between GH concentration and the lipolytic actions of GH is more linear, while the relationship between GH and excess extracellular water is more curvilinear. The sodium-retaining effect of GH seems to be mediated by stimulation of the Na(+)-K+ pump. At higher GH levels, the pump activity is counteracted by an alleged sodium transport inhibitor. In GH-deficient children, GH treatment is followed by rapid loss of adipose tissue and muscular gain. The influence of GH on body composition in GH-deficient adults has recently received attention. Compared to normal subjects, these patients are overweight and have decreased cell mass. Replacement treatment with GH restores body composition towards normal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245966     DOI: 10.1159/000181579

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  12 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly.

Authors:  Miriam A Bredella; Melanie Schorr; Laura E Dichtel; Anu V Gerweck; Brian J Young; Whitney W Woodmansee; Brooke Swearingen; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

3.  Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study.

Authors:  Carla Giordano; Alessandro Ciresi; Marco Calogero Amato; Rosario Pivonello; Renata Simona Auriemma; Ludovica Francesca Stella Grasso; Aldo Galluzzo; Annamaria Colao
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

4.  Free intracellular and protein bound amino acids in tissues as affected by a mixed beta-adrenergic agonist.

Authors:  M Rguez-Mariscal; A S Del Barrio; J Larralde; J A Martínez
Journal:  Experientia       Date:  1993-04-15

5.  Herniation of cerebellar tonsils in acromegaly: prevalence, pathogenesis and clinical impact.

Authors:  Renzo Manara; Giulia Bommarito; Silvia Rizzati; Chiara Briani; Alessandro Della Puppa; Valentina Citton; Eva Zanchetta; Fabio Zerbo; Mario Ermani; Chiara Martini; Franco Mantero; Nicola Sicolo; Pietro Maffei; Carla Scaroni
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

Review 6.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

7.  Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

Authors:  Pamela U Freda; Wei Shen; Steven B Heymsfield; Carlos M Reyes-Vidal; Eliza B Geer; Jeffrey N Bruce; Dympna Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

8.  Growth hormone protects human lymphocytes from irradiation-induced cell death.

Authors:  Laurence Lempereur; Daria Brambilla; Giovanna Maria Scoto; Maria D'Alcamo; Vincent Goffin; Lucia Crosta; Tullio Palmucci; Liborio Rampello; Renato Bernardini; Giuseppina Cantarella
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

9.  Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis.

Authors:  A Schibler; R von der Heiden; P Birrer; P E Mullis
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

10.  Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population.

Authors:  Mikkel Andreassen; Ilan Raymond; Per Hildebrandt; Caroline Kistorp; Camilla Rathcke; Henrik Vestergaard; Jens Faber; Lars Ostergaard Kristensen
Journal:  Inflamm Res       Date:  2010-01-03       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.